This article was originally published in The Gray Sheet
Photodynamic therapy for wet age-related macular degeneration should be used only for individuals with entirely classic subfoveal choroidal neovascularization and visual acuity of 6/60 or better, UK's National Institute for Clinical Excellence says in Oct. 14 appraisal consultation document. The paper further recommends that PDT be "used in predominantly (but not entirely)" classic CNV associated with wet AMD only as part of ongoing or new clinical trials designed to generate relevant outcome data, including data on quality of life and costs. CMS announced in March that available data were "not adequate" to grant coverage of an off-label occult-only indication...
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.